Urgent research is required to identify synergistic combinations (e.g., FSP1 inhibitors with GPX4 inhibitors, ferroptosis inducers with IDO1/m6A inhibitors, and ferroptosis inducers with immune checkpoint blockade) that can simultaneously bypass multiple resistance pathways across diverse GBM subclones. The gene discussed is GPX4; the disease is glioblastoma.